儿童经典型霍奇金淋巴瘤基线与中期18F-FDG PET/CT定量参数变化的预后影响
该单中心回顾性研究纳入48例儿童经典型霍奇金淋巴瘤患者,分析基线与2周期化疗后中期18F-FDG PET/CT定量参数变化对无进展生存期(PFS)的预后价值。基线定量参数在进展组与非进展组间无显著差异;中期PET中三种分割方法所得定量参数较高及ΔSUVmax、ΔMTV(41)、ΔMTV(42)、ΔTLG(41)、ΔTLG(med)下降较少与较差PFS相关。多因素Cox回归显示i-SUVmax(HR 1.20,P<0.001)和ΔMTV(41)(HR 0.965,P=0.007)为PFS的独立危险因素。
要点
- 基线18F-FDG PET/CT定量参数在进展组与非进展组间无显著差异。
- 中期PET中3种分割方法(%41 SUVmax、%42 SUVmax、纵隔SUVmax)定量参数较高及ΔSUVmax、ΔMTV(41)、ΔMTV(42)、ΔTLG(41)、ΔTLG(med)下降较少与较差PFS相关。
- 多因素Cox回归显示i-SUVmax(HR 1.20,P<0.001)和ΔMTV(41)(HR 0.965,P=0.007)为PFS独立危险因素。
核心结论
- 中期18F-FDG PET参数及化疗后变化具有显著预后价值,定量评估超越视觉评估可能有助于儿童经典型霍奇金淋巴瘤的风险适应和个体化治疗。
研究设计与样本
- 单中心回顾性研究,纳入2019年1月至2023年10月间接受基线与2周期化疗后中期18F-FDG PET/CT的儿童经典型霍奇金淋巴瘤患者,最终48例符合纳入标准(32例男性,中位年龄12岁)。
- 采用4种分割方法(%41 SUVmax、%42 SUVmax、纵隔SUVmax、肝脏SUVmax)评估代谢肿瘤体积(MTV)、总病灶糖酵解(TLG)及其2周期化疗后变化(ΔMTV、ΔTLG)。
- 采用Cox回归分析评估参数对无进展生存期(PFS)的预后意义,Kaplan-Meier分析评估基于最佳截断值的生存差异。
主要发现
- 中位随访21个月(范围5-52个月)期间,22.9%(n=11)的患者出现疾病进展。
- 基线18F-FDG PET/CT定量参数在进展组与非进展组间无显著差异。
- 中期18F-FDG PET/CT中,3种分割方法(%41 SUVmax、%42 SUVmax、纵隔SUVmax)的定量参数较高及ΔSUVmax、ΔMTV(41)、ΔMTV(42)、ΔTLG(41)、ΔTLG(med)下降较少与较差PFS相关。
- 多因素Cox回归分析中,i-SUVmax(HR 1.20,P<0.001)和ΔMTV(41)(HR 0.965,P=0.007)被确定为PFS的独立危险因素。
关键数值与推荐
- i-SUVmax的多因素Cox回归HR为1.20(P<0.001)。
- ΔMTV(41)的多因素Cox回归HR为0.965(P=0.007)。
- 中位随访21个月(范围5-52个月),疾病进展率22.9%(n=11)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18 F-FDG PET/CT plays a crucial role in the evaluation and management of pediatric classic Hodgkin lymphoma (cHL). In addition to visual assessment, quantitative parameters also have prognostic value. This study aimed to investigate the prognostic significance of PET parameters, with a particular focus on the changes observed in these parameters after 2 cycles of chemotherapy, in pediatric cHL patients. PATIENTS AND METHODS: The study was designed as a single-center, retrospective. A total of 198 pediatric cHL patients who underwent baseline and post-2-cycle chemotherapy interim 18 F-FDG PET/CT imaging between January 2019 and October 2023 were included in the study. Four different segmentation methods (%41 SUVmax, %42 SUVmax, mediastinal SUVmax, and liver SUVmax) were applied. Quantitative parameters, including metabolic tumor volume (MTV), total lesion glycolysis (TLG), and their changes after 2 chemotherapy cycles (ΔMTV, ΔTLG), were evaluated for each segmentation method. The prognostic significance of these parameters for progression-free survival (PFS) was assessed using Cox regression analysis, while survival differences based on optimal cutoff values were evaluated using Kaplan-Meier analysis. RESULTS: A total of 48 pediatric cHL patients (32 males, median age: 12 y) met the inclusion criteria. During a median follow-up of 21 months (range: 5-52 mo), disease progression was observed in 22.9% of the patients (n=11). Baseline 18 F-FDG PET/CT quantitative parameters did not show significant differences between progression and nonprogression groups. However, on interim 18 F-FDG PET/CT, higher values of quantitative parameters from 3 segmentation methods (%41 SUVmax, %42 SUVmax, and mediastinal SUVmax) and lower postchemotherapy reductions in ΔSUVmax, ΔMTV (41) , ΔMTV (42) , ΔTLG (41) , and ΔTLG (med) were associated with poor PFS. In multivariate Cox regression analysis, i-SUVmax (Hazard ratio, HR: 1.20, P <0.001) and ΔMTV (41) (HR: 0.965, P =0.007) were identified as independent risk factors for PFS. CONCLUSIONS: Interim 18 F-FDG PET parameters and postchemotherapy changes demonstrated significant prognostic value. Quantitative evaluation beyond visual assessment may contribute to risk-adapted and personalized treatment approaches in pediatric cHL.
引用
- Kartal MO, Kartal AS, Kurucu B, et al. Prognostic Impact of Quantitative Changes Between Baseline and Interim 18 F-FDG PET/CT in Pediatric Classic Hodgkin Lymphoma. Clin Nucl Med. 2025. PMID: 40173294. doi:10.1097/RLU.0000000000005874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。